New application of FAM177A1

• Main Authors: HUANG KAI, CHEN MIN, ZHU FENG, YUAN LIN, LIANG MINGLU, BU SHICHEN
• Format: Patent
• Language: Chinese; English
• Published: 03.01.2023
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS OR TEST PAPERS THEREFOR; COMPOSITIONS THEREOF; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES; CULTURE MEDIA; ENZYMOLOGY; HUMAN NECESSITIES; HYGIENE; INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES; MEASURING; MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS; MEDICAL OR VETERINARY SCIENCE; METALLURGY; MICROBIOLOGY; MICROORGANISMS OR ENZYMES; MUTATION OR GENETIC ENGINEERING; PHYSICS; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; PROCESSES OF PREPARING SUCH COMPOSITIONS; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS; SPIRITS; TESTING; VINEGAR; WINE

The invention belongs to the field of application research of FAM177A1, and particularly relates to a novel application of FAM177A1. Mainly discloses application of a preparation for detecting FAM177A1 in preparation of a detection product for myocardial cell hypertrophy diseases. The invention relates to an application of FAM177A1 or an expression promoter thereof in preparation of drugs for treating myocardial cell hypertrophy diseases. The invention relates to an application of FAM177A1 in preparation of drugs for treating diseases induced by MAPK/ERK pathway activation. The invention relates to an application of FAM177A1 in preparation of an MAPK enzyme non-diagnostic treatment activity inhibitor. According to the application disclosed by the invention, the FAM177A1 has an inhibiting effect on MAPK, and the FAM177A1 can become an anti-cardiac hypertrophy target spot, so that occurrence and development of cardiac hypertrophy are prevented or treated; the FAM177A1 can also be applied as a product for diagno